RenovoRx to Highlight Record Revenue and Clinical Progress at AGP Showcase
Event summary
- RenovoRx CEO Shaun Bagai and CFO Mark Voll to present at AGP's Virtual Annual Healthcare Company Showcase on May 20, 2026.
- Company reports record Q1 2026 revenue of $563,000 from RenovoCath, up from $1.1 million in full-year 2025.
- Phase III TIGeR-PaC trial enrollment expected to close in June 2026, with final data anticipated in mid-to-late 2027.
- RenovoRx expanding RenovoCath adoption at high-volume cancer centers, including NCI-designated facilities.
The big picture
RenovoRx's presentation comes amid growing interest in targeted oncology therapies, with its RenovoCath device gaining traction as a standalone drug-delivery solution. The company's focus on capital-efficient investigator-initiated trials and registry studies underscores a strategic shift toward broadening clinical evidence while managing costs. With first-quarter 2026 revenue surpassing full-year 2025 figures, RenovoRx is positioning itself for potential inflection points in both commercial and clinical domains.
What we're watching
- Commercial Momentum
- Whether RenovoRx can sustain accelerating RenovoCath adoption at top-tier cancer centers.
- Clinical Milestones
- The pace at which the TIGeR-PaC trial progresses toward final data readout in 2027.
- Regulatory Pathway
- How Orphan Drug Designation for IAG may impact future market exclusivity and commercial strategy.
Related topics